Nasdaq

Spotlight on Recursion Pharmaceuticals: Analyzing the Surge in Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Recursion Pharmaceuticals. Looking at options history for Recursion Pharmaceuticals (NASDAQ:RXRX) we detected 9 trades. If ...
GEN

Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...
manilatimes

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial ...

Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMT Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical ...
The Globe and Mail

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial ...

Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide ...